{"id":8238,"date":"2017-09-21T11:41:01","date_gmt":"2017-09-21T15:41:01","guid":{"rendered":"https:\/\/medicarereport.org\/?p=8238"},"modified":"2017-09-21T11:41:01","modified_gmt":"2017-09-21T15:41:01","slug":"alnylams-rare-disease-drug-shines-in-trial-paving-way-for-a-brand-new-class-of-medicines","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=8238","title":{"rendered":"Alnylam\u2019s rare disease drug shines in trial, paving way for a brand-new class of medicines"},"content":{"rendered":"<p>(By Adam Feuerstein for ST<em>A<\/em>T)<\/p>\n<p class=\"danger-zone\">The age of RNA interference drugs has arrived.<\/p>\n<p class=\"danger-zone\">Alnylam Pharmaceuticals announced positive results Wednesday from a closely watched phase 3 clinical trial of patisiran, the company\u2019s lead drug designed to treat a rare nerve disorder known as familial amyloid polyneuropathy (FAP.) <a href=\"https:\/\/www.statnews.com\/2017\/09\/20\/alnylam-drug-success\/?utm_source=STAT+Newsletters&amp;utm_campaign=fd42b654f4-Pharmalot&amp;utm_medium=email&amp;utm_term=0_8cab1d7961-fd42b654f4-149624405\">Continue reading article here..<\/a><\/p>\n<p class=\"danger-zone\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Adam Feuerstein for STAT) The age of RNA interference drugs has arrived. Alnylam Pharmaceuticals announced positive results Wednesday from<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,14],"tags":[],"class_list":["post-8238","post","type-post","status-publish","format-standard","hentry","category-health-care-general","category-medical-technology"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/8238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8238"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/8238\/revisions"}],"predecessor-version":[{"id":8239,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/8238\/revisions\/8239"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}